Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroTech Medical (Hangzhou) Co., Ltd.
微泰醫療器械(杭州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2235)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF INDICATION FOR CHILDREN AND ADOLESCENT USERS OF PATCH INSULIN PUMP SYSTEM

This announcement is published by MicroTech Medical (Hangzhou) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, for the purpose of keeping its shareholders (the "**Shareholders**") and potential investors informed of the latest development of the Group.

The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of the Company is pleased to announce that the indication for children and adolescent users of one of our core product (the "**Core Product**"), Equil Patch Insulin Pump, has recently been approved by the National Medical Products Administration (the "**NMPA**"). This approval further expands the applicable scope of our Core Product from the original "adult diabetic patients" to children and adolescents aged 3–17, providing a new treatment option for millions of domestic children and adolescent diabetic patients.

The clinical trial for the expansion of indication was led by the Children's Hospital of Zhejiang University School of Medicine* (浙江大學醫學院附屬兒童醫院) and jointly completed by six top national children's hospitals.. It fully demonstrates the safety and effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) in the treatment of diabetes of children and adolescents.

The patch insulin pump is mainly used for diabetic patients who need insulin therapy. It can achieve accurate and continuous insulin infusion, simulate the physiological insulin secretion mode of the human body to the greatest extent, and help diabetic patients better manage their blood glucose. Compared with traditional tube insulin pumps, this product has the advantages of more accuracy and insulin delivery safety, more conveniency and wearing and use flexibility, more economical semi-disposable use, more privacy, and no problems of tube blockage and tube entanglement.

The expansion of this indication reflects the Company's strong independent research and development capabilities in the field of diabetes monitoring, treatment and management. At the same time, it will further strengthen the Company's leading position in the industry and help realize the strategic enlargement of the product's market share. In the future, the Company will continue to focus on the global development of diabetes monitoring, treatment and management methods, and promote technological and product innovation in related fields.

The Company reminds the Shareholders and potential investors that the production, sales and the resulting income of the above-mentioned products are affected by many factors such as market changes. Shareholders and potential investors of the Company are requested to exercise caution when dealing with the shares of the Company.

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, September 24, 2025

As at the date of this announcement, the executive Directors of the Company are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors of the Company are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors of the Company are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.

* *The English translation of the Chinese name denoted in this announcement is for illustration purpose only. Should there be any inconsistencies, the Chinese name shall prevail.*